Isaac O. Ajadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Isaac O. Ajadi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Kehinde Samuel Olaniyi
Cardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
2 shared publications - Mary B. Ajadi
Department of Chemical Pathology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
2 shared publications - Olabimpe Caroline Badejogbin
Department of Physiology, School of Basic Medical Sciences, Babcock University, Ilishan-Remo, Ogun State, Nigeria, babcock.edu.ng
2 shared publications - Adesola A. Oniyide
Cardio/Endo-Metabolic and Epigenetics Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
1 shared publication - Chukwubueze L. Atuma
Cardio/Endo-Metabolic and Epigenetics Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria
1 shared publication - Esosa Stephanie Areloegbe
Afe Babalola University
1 shared publication
Latest Publications
- 12 March 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (3) , 1-10
Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS
Background: Polycystic ovary syndrome (PCOS) is a common endocrinometabolic disorder affecting women of reproductive age, characterized by hormonal imbalances, irregular menstrual cycles, and often, infertility. Hypothalamic amenorrhea, a condition marked by the cessation of menstruation due to disruptions in the hypothalamic-pituitary-gonadal axis, is a frequent manifestation in PCOS. Probiotics, beneficial microorganisms known for improving metabolic health, have shown promise in restoring hormonal balance and enhancing fertility. In this study, we hypothesize that probiotics would ameliorate hypothalamic amenorrhea by modulating hypothalamic kisspeptin and reducing inflammation in a rat model of PCOS. Methods: Eight (8)-week-old female Wistar rats were grouped into four with n = 5. Letrozole administration (1 mg/kg, p.o.) for 21 days induced PCOS, thereafter the animals were treated with probiotics (3 × 109 CFU, p.o.), while control animals received distilled water. The treatment lasted for six weeks. Results: Reduced insulin sensitivity, hyperinsulinemia, ovarian dysfunction with evidence of disrupted steroid hormone levels (testosterone/17β-Estradiol) and cystic follicles as well as hypothalamic lipid accumulation, elevated inflammatory markers (NF-kB/TNF-α) and antioxidant depletion (GSH/NrF2), which are accompanied by decreased level of kisspeptin. Nonetheless, administration of probiotics reversed these pathological alterations by enhancement of hypothalamic kisspeptin and suppression of inflammatory response. Conclusions: Altogether, the present results demonstrate that probiotics significantly ameliorated hypothalamic amenorrhea by mitigating hypothalamic lipid accumulation, suppressed inflammation, and replenished antioxidants. Crucially, probiotics enhanced hypothalamic kisspeptin levels, a key regulator of reproductive function, highlighting their potential as a therapeutic strategy for restoring ovarian function in PCOS. Graphical abstract Graphical abstract showing the ameliorative effect of probiotics on hypothalamic amenorrhea in letrozole-induced PCOS rat model. Gonadotropin releasing hormone (GnRH); Follicle stimulating hormone (FSH); Luteinizing hormone (LH).
- 12 March 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (3) , 1-10
Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS
Background: Polycystic ovary syndrome (PCOS) is a common endocrinometabolic disorder affecting women of reproductive age, characterized by hormonal imbalances, irregular menstrual cycles, and often, infertility. Hypothalamic amenorrhea, a condition marked by the cessation of menstruation due to disruptions in the hypothalamic-pituitary-gonadal axis, is a frequent manifestation in PCOS. Probiotics, beneficial microorganisms known for improving metabolic health, have shown promise in restoring hormonal balance and enhancing fertility. In this study, we hypothesize that probiotics would ameliorate hypothalamic amenorrhea by modulating hypothalamic kisspeptin and reducing inflammation in a rat model of PCOS. Methods: Eight (8)-week-old female Wistar rats were grouped into four with n = 5. Letrozole administration (1 mg/kg, p.o.) for 21 days induced PCOS, thereafter the animals were treated with probiotics (3 × 109 CFU, p.o.), while control animals received distilled water. The treatment lasted for six weeks. Results: Reduced insulin sensitivity, hyperinsulinemia, ovarian dysfunction with evidence of disrupted steroid hormone levels (testosterone/17β-Estradiol) and cystic follicles as well as hypothalamic lipid accumulation, elevated inflammatory markers (NF-kB/TNF-α) and antioxidant depletion (GSH/NrF2), which are accompanied by decreased level of kisspeptin. Nonetheless, administration of probiotics reversed these pathological alterations by enhancement of hypothalamic kisspeptin and suppression of inflammatory response. Conclusions: Altogether, the present results demonstrate that probiotics significantly ameliorated hypothalamic amenorrhea by mitigating hypothalamic lipid accumulation, suppressed inflammation, and replenished antioxidants. Crucially, probiotics enhanced hypothalamic kisspeptin levels, a key regulator of reproductive function, highlighting their potential as a therapeutic strategy for restoring ovarian function in PCOS. Graphical abstract Graphical abstract showing the ameliorative effect of probiotics on hypothalamic amenorrhea in letrozole-induced PCOS rat model. Gonadotropin releasing hormone (GnRH); Follicle stimulating hormone (FSH); Luteinizing hormone (LH).
- 16 November 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1275-1287
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome
Purpose Polycystic ovarian syndrome (PCOS) has been associated with cardiovascular risks and comorbid pathologies, particularly cardiorenal disorder. Short-chain fatty acids (SCFAs), especially butyrate, are essential fatty acids that regulate metabolic health and ameliorate granulosa inflammation in PCOS. However, the effect of butyrate on cardiorenal damage associated with PCOS is unknown. This study investigated the impact of SCFA and butyrate on cardiorenal abnormalities in PCOS rat model and the probable involvement of paraoxonase-1 (PON-1). Methods Eight-week-old female Wistar rats were allotted into three groups, n = 5, namely control (CTL), PCOS (LEZ), and LEZ + BUT. Induction of PCOS with letrozole (1 mg/kg) lasted for 21 days, while treatment with butyrate (200 mg/kg) commenced after the induction and lasted for 6 weeks uninterruptedly. Results PCOS rats showed hyperandrogenism, multiple ovarian cysts, disrupted metabolic indices (fasting insulin and homeostatic model of insulin resistance), and increased (p < 0.05) plasma troponin T, urea, and creatinine, as well as increased cardiac/renal stroma cell–derived factor-1/caspase-6, malondialdehyde/nuclear factor-kappaB, transforming growth factor-β1, and renal ϒ-glutamyl transferase, while a significant decrease (p < 0.05) in systemic nitric oxide/endothelial nitric oxide synthase and cardiac/renal hypoxia-inducible factor-1α and nuclear factor erythroid 2–related factor 2, which were accompanied with a decreased level of PON-1. These systemic and cardiorenal derangements were reversed by butyrate administration. Conclusions The results demonstrate the therapeutic benefits of SCFAs, butyrate, against cardiorenometabolic disorder in a model of PCOS. This beneficial effect is accompanied by an elevated level of PON-1. The present data possibly provides a preclinical relevance for the management of cardiorenal syndrome in PCOS.
- 16 November 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1275-1287
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome
Purpose Polycystic ovarian syndrome (PCOS) has been associated with cardiovascular risks and comorbid pathologies, particularly cardiorenal disorder. Short-chain fatty acids (SCFAs), especially butyrate, are essential fatty acids that regulate metabolic health and ameliorate granulosa inflammation in PCOS. However, the effect of butyrate on cardiorenal damage associated with PCOS is unknown. This study investigated the impact of SCFA and butyrate on cardiorenal abnormalities in PCOS rat model and the probable involvement of paraoxonase-1 (PON-1). Methods Eight-week-old female Wistar rats were allotted into three groups, n = 5, namely control (CTL), PCOS (LEZ), and LEZ + BUT. Induction of PCOS with letrozole (1 mg/kg) lasted for 21 days, while treatment with butyrate (200 mg/kg) commenced after the induction and lasted for 6 weeks uninterruptedly. Results PCOS rats showed hyperandrogenism, multiple ovarian cysts, disrupted metabolic indices (fasting insulin and homeostatic model of insulin resistance), and increased (p < 0.05) plasma troponin T, urea, and creatinine, as well as increased cardiac/renal stroma cell–derived factor-1/caspase-6, malondialdehyde/nuclear factor-kappaB, transforming growth factor-β1, and renal ϒ-glutamyl transferase, while a significant decrease (p < 0.05) in systemic nitric oxide/endothelial nitric oxide synthase and cardiac/renal hypoxia-inducible factor-1α and nuclear factor erythroid 2–related factor 2, which were accompanied with a decreased level of PON-1. These systemic and cardiorenal derangements were reversed by butyrate administration. Conclusions The results demonstrate the therapeutic benefits of SCFAs, butyrate, against cardiorenometabolic disorder in a model of PCOS. This beneficial effect is accompanied by an elevated level of PON-1. The present data possibly provides a preclinical relevance for the management of cardiorenal syndrome in PCOS.